AARDEX Group

Harnessing Smart Pill Bottles to Improve Patient Adherence in Clinical Research

smart pill bottles

“Nothing stops a drug from working like not taking it, making patient adherence one of the most important factors to consider when designing a clinical trial.” 
– Bernard Vrijens, Scientific Lead, AARDEX® Group

Poor patient adherence is a problem that has gone “unsolved” for decades. But combining smart pill bottle technology with individualized feedback can drive the adherence that proves the investigational product efficacy and underwrites approvals.

In this case study, we set out the crucial role of medicine-taking behavior in clinical research and explain how using AARDEX® Group’s Smart Pill Bottle, MEMS® Caps, in a study of Gilead’s Truvada helped inform the FDA’s recommended approach to tackling poor patient adherence in clinical trials, as set out in its Enrichment Strategies for Clinical Trials to Support Determination of Effectiveness of Human Drugs and Biological Products.

Share This Post

You may also like...

Breaking News

Is Neglecting Medication Adherence in Neurology Drug Trials Putting Patients at Risk?

The list of Neurological conditions is considerable, with epilepsy, Alzheimer’s disease, dementia, stroke, migraine, multiple sclerosis, Parkinson’s disease, neuro infections, and brain tumors, all attributed to this category of disease. Hundreds of millions of people worldwide are affected by neurological

Bias in clinical Research
Breaking News

Unmasking Bias in Clinical Research: A Historical Perspective

It’s an uncomfortable truth that decision-making is a murky business. While we would all like to think that our actions and the choices underpinning them are rooted in logic, integrity, and reason, the truth is not entirely clear-cut. In reality,